Myrtelle Publishes Promising Interim Results for Canavan Disease Therapy
Myrtelle Inc. has announced significant interim results from its Phase 1/2 clinical trial of the investigational gene therapy rAAV-Olig001-ASPA (MYR-101) for Canavan disease, following publication in Nature Medicine on September…